News
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...
The endothelin pathway plays a key role in regulating renal blood flow, glomerular filtration rate, and tubular transport, and its overactivity has been linked to IgAN.
Schlaich said the endothelin pathway has been previously “implicated in the pathogenesis of hypertension,” particularly in sodium and water retention; the endothelin A and B receptors exert their ...
Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension ...
SAN FRANCISCO, July 20, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases is pleased to ...
“Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition.
Hong: Current therapeutic interventions for PAH primarily target three main pathways: the endothelin pathway, the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway and the prostacyclin ...
These channels open when they sense an increase in the cellular levels of a chemical messenger called inositol 1,4,5-trisphosphate, IP3, which is produced after the binding of a hormone called ...
These findings suggest a potentially transformative approach for the treatment of glaucoma by targeting the endothelin pathway, a well-established mediator of vascular dysfunction in the disease.
The research team, led by Professor Masashi Kato and Dr. Takumi Kagawa, discovered that luteolin prevents hair graying by ...
Tryvio, the first approved medicine to target the endothelin pathway as opposed to the typical methods of other antihypertensive therapies, received the nod from the FDA in March to treat high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results